Kojiro Shimozuma
Kusatsu, 5258577, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan.
Journal: PharmacoEconomics - open
Published: July 04, 2025
Vignette-Based Estimation of Utilities in Patients With Metastatic Triple-Negative Breast Cancer in Japan.
Journal: Value in health regional issues
Published: June 18, 2025
Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan.
Journal: Value in health regional issues
Published: June 18, 2025
Japanese value set for the Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D) cancer-specific preference-based quality of life instrument.
Journal: Health and quality of life outcomes
Published: January 27, 2025
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors.
Journal: Japanese journal of clinical oncology
Published: October 31, 2024
Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: March 18, 2024
Interpretation of clinically meaningful change in cancer palliative care patients' quality of life: minimally important difference for EORTC QLQ-C15-PAL.
Journal: Journal of patient-reported outcomes
Published: November 03, 2023
Perceptions regarding the concept and definition of patient-reported outcomes among healthcare stakeholders in Japan with relation to quality of life: a cross-sectional study.
Journal: Health and quality of life outcomes
Published: September 07, 2023
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Journal: Value in health regional issues
Published: February 21, 2023
How to select and understand guidelines for patient-reported outcomes: a scoping review of existing guidance.
Journal: BMC health services research
Published: February 13, 2023
Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Journal: Journal of gastroenterology
Published: January 14, 2023
Last Updated: 09/26/2026